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Radioiodine-131 (RAI) is an isotope of the chemical element iodine and is  
commonly used for hyperthyroidism, including Graves’ disease. It is given orally, 
and its concentration in the thyroid gland. The RAI transport involves a natrium 
iodide symporter (NIS) role that brings two cations sodium (Na+) and one anion 
of iodide (I-) across the membrane. The process is facilitated by the enzyme Na+/
K+ ATPase. RAI is a beta (β) and gamma (γ) particles emitter. β particle is used for 
therapy and γ particle for imaging (theranostic). β particle inhibits cell growth by 
inducing cell death through apoptosis or necrosis of some of the sufficient thyroid 
cells. The aim of RAI therapy in Graves’ disease is to control hyperthyroidism 
and render the patient hypothyroidism. It is easier to manage patients with hypo-
thyroidism with levothyroxine and fewer complications. This review will focus 
on RAI’s therapeutic approach in Graves’ disease, including patient preparation, 
selecting activity dose, adverse events, contraindication, controversies issues such 
as malignancy and fertility, the follow-up to ensuring the patient remains euthyroid 
or need a replacement therapy if they become hypothyroidism. RAI therapy is safe 
as definitive therapy and cost-effective for Graves’ disease therapy.
Keywords: hyperthyroidism, hypothyroidism, malignancy, pregnancy,  
replacement therapy
1. Introduction
Graves’ disease is an autoimmune disorder that affects the thyroid gland, and 
it causes 50–80% of hyperthyroid cases and is associated with a firm diffuse goiter 
[1–3]. Its etiology is not entirely understood. The disease occurs in patients with 
having a genetic history and combination with environmental factors and lifestyles. 
Graves’ disease (GD) is characterized by elevated thyroid-stimulating receptor anti-
bodies with increased thyroid hormone production [4–6]. GD can also affect other 
organs, including the eyes and skin. The annual incidence rate has been estimated 
at 14–50 cases per 100,000 persons. The peak incidence is between 30–50 years. 
Even though the disease may affect every age, the incidence is higher in women than 
men, with a 6:1 ratio [2, 5].
Graves’ disease treatments depend on the presentation. The treatment consists 
of symptomatic therapy and reduction of thyroid hormone synthesis. The symp-
tomatic therapy, such as a beta-adrenergic blocker, is given for patients with tachy-
cardia, a history of cardiovascular disease, and elderly patients [2, 6]. Therapies 
for reducing thyroid hormone synthesis are antithyroid drugs (ATDs), radioactive 
iodine (RAI), and thyroidectomy [2, 3, 6–8]. All three options have advantages and 
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disadvantages. There is no consensus on which one is the best choice, and it is one 
of the more debatable issues. The treatment choice is likely to be influenced by local 
availability, treatment cost, patient’s preferences, and socio-economy that caused 
vary from country to country.
Antithyroid drugs are widely used in Europe and most of Asia as first-line 
therapy. However, RAI is used by most physicians in the United States of America. 
[3, 6–8]. Hertz and Roberts were used radioiodine I-130 for the first time on March 
31, 1941, for hyperthyroidism treatment [9, 10]. Its radiation was delivered rapidly 
to the thyroid cells over a day or two. Since the Atomic Energy Commission was 
allowed to supply the fission products for peaceful medical use in August 1946, 
I-130 was replaced by I-131 because I-131 was much cheaper [9]. RAI is used for 
therapy and imaging (theranostic). It is a beta (β) and gamma (γ) emitter with a 
half-life of 8.05 days. A β particle has a peak energy of 0.606 MeV, with a maximum 
range of ~3 mm in the tissue used for therapy. The peak of γ particle is 0.364 MeV is 
used for imaging [4, 11, 12]. The longer physical half-life of RAI ensures long-term 
irradiation of the target tissues, becoming a potential advantage.
RAI therapy aims to treat hyperthyroidism by destroying sufficient thyroid 
cells to reach either euthyroid or hypothyroid conditions. Radioactive iodine is 
safe as definitive therapy, cure rates ~80–90%, and cost-effective, rarely or minor 
side-effects. [4, 6, 7, 11–14]. The choice of therapy depends on the patient’s prefer-
ence. The choice of therapy should take into account local availability and cost-
effectiveness. In practical terms, RAI is administrated as an outpatient visit, and 
it is an advantage. RAI is recommended for optimal treatment of Graves’ disease 
by the American Thyroid Association (ATA) and American Association of Clinical 
Endocrinologists (AACE) guidelines for the management of thyrotoxicosis 2011 and 
ATA 2016 [3, 6, 15]. The recent guidelines of the United Kingdom (UK) National 
Institute for Health and Care Excellence (NICE) recommend that radioiodine 
should now be the first-line treatment for Graves’ disease in the UK [7].
2. Transport radioiodine
RAI is administrated in a capsule or liquid. Once it is ingested, it is quickly 
absorbed into the bloodstream in the gastrointestinal (GI) tract. It is taken up by 
Figure 1. 
Natrium iodide symporter brings two cations of sodium (Na+) and one anion of iodide (I−) cross the epithelial 
thyroid cells’ at the basolateral membrane. The process is facilitated by the enzyme Na+/K+ ATPase.
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thyroid cells through active transport, which is the same natural iodine process. The 
transport involves a natrium iodide symporter (NIS) role that brings two cations 
sodium (Na+) and one anion of iodide (I−). The process is facilitated by an enzyme 
Na+/K+ ATPase, as shown in Figure 1. NIS is a transmembrane glycoprotein that 
contains 13 membrane-spanning segments and three N-linked carbohydrates. It 
resides in the basolateral membrane of epithelial thyroid cells [16–20]. Besides 
the thyroid cell, NIS is expressed by extra-thyroid tissues [20]. NIS expression 
increased RAI uptake for diagnostic and therapy in thyroid extra-thyroid organ.
3. The mechanism action of RAI
β particle of RAI inhibits cell growth by inducing cell death through apoptosis 
or necrosis. Cell responses to radiation are influenced by various factors that lead to 
different responses between cells. The amount of RAI radiation received by cells is 
affected by the capture and accumulation of RAI and its biological half-life, which 
correlates with the effects. Cell responses to radiation are influenced by the cell’s 
sensitivity and the complexity of the cells’ micro-environments [21, 22]. Due to the 
small therapeutic range of β particles within the tissues, naturally, no β particles 
escape from the thyroid. So, the remaining non-target tissue (i.e., parathyroid glands) 
still safe even though high activity RAI dose is given to the patients. [4, 11, 23].
A β particle of RAI has a low Linear Energy Transfer (LET) value (0.2 KeV/
μm). It causes cell death, direct and indirect. The decay of radioisotopes in the cell 
(self-dose) cause DNA damage through direct breakage of molecular bonds. The 
formation of free radicals or the decay of radioisotopes in adjacent cells (cross-fire) 
indirectly causes cell death, as shown in Figure 2. The condition leads to a reduction 
of thyroid function and diminished thyroid size [24, 25].
Figure 2. 





Many studies reported various approaches to RAI therapy published by different 
institutions. It remains a matter of debate when choosing the treatment protocols, 
whether a calculated dose that considers radioiodine uptake (RAIU) and thyroid 
volume measurements versus a fixed-dose, or a high dose versus a low dose, or 
whether short term versus long term medical management. RAI administrates as 
low as reasonably achievable (ALARA) dose that is an essential principle for radia-
tion treatment [23, 25].
5. Radioiodine dose
RAI therapy is well established for the definitive treatment of GD. However, 
Its approach remains controversial due to differing treatment control goals. It is 
between hyperthyroidism versus avoidance of hypothyroidism. Various methods 
of RAI doses have been used to deliver adequate radiation to the thyroid gland. 
Radiation dose to the thyroid depends on the RAI uptake, thyroid volume, and 
biologic half-life of the RAI. Actually, RAI activity dose measured based an amount 
of the radiation delivered to the thyroid gland rather than administered activity, but 
few publications confirm this unequivocally [23]. Three approaches for determining 
the administered RAI activity doses. 1. Based on the calculation of thyroid volume 
and the RAI uptake 24 hours. 2. Based on thyroid volume, RAI uptake, effective 
half-life. 3. Fixed activity dose [4, 11].
In calculation approaches, the thyroid volume, RAI uptake, and effective half-
life are factors determine the activity dose. It is recommended a delivered activity of 
RAI about 3–8 MBq (80–220 μCi) per gram of thyroid mass, with absorbed radia-
tion dose 100–150 Gy to restore a euthyroid status, whereas the total ablation dose 
is in the range 200–300 Gy [12, 14, 23]. Naturally, the normal thyroid mass is about 
20 grams. Ultrasound, x-ray/MRI studies, and scintigraphy thyroid can be used 
to evaluate thyroid volume. However, ultrasonography is superior to all of these 
techniques because of its relatively low cost, wide availability, ease of technically.
The RAI uptake should be appropriately prepared to ensure its real thyroid 
uptake. The patient should be advised to avoid meals for at least 2 hours before and 
2 hours after the oral administration of RAI for the test. The thyroid uptake can also 
be measure by intravenous administration of Tc-99 m pertechnetate. The pertech-
netate is trapped but not be organification by the thyroid. The measurement usually 
after 20 minutes of the injection [6, 11, 23]. GD uptakes usually high unless the 
patient has a history of iodine intake recently. However, the calculated dose versus 
fixed-dose effectiveness is an equally successful outcome [6, 26]. Radioactive iodine 











An effective half-life is needed for an accurate absorbed dose calculation to 
the thyroid [6, 11]. Effective half-life is the combination of the physical half-life 
(constant for a particular nucleus) and the biological half-life (varies from patient 
to patient). A radionuclide in a living tissue decays in two ways, physical decay 
and biological elimination from the body is called biological half-life. The effective 
half-life of RAI in the thyroid can be determined by measuring its uptake at several 
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different periods following RAI administration. It may vary from 1.2 to 7.5 days in 
hyperthyroidism (i.e., the variation factor is 6.25). The effective half-life calculation 
is cumbersome. It has a lot of calculations and assumptions that may have a human 
error. Effective half-life calculation will increase the accuracy of RAI activity dose 
[11]. However, the outcome has not been shown to be better, so the method is rarely 
used [6].
Fixed-dose of RAI activities is a simple protocol and convenient to use. It can 
be administered as a single dose and be repeated as necessary, with a range of 
185–740 MBq (5- 20 mCi). The administration dose is given based on validated 
clinical parameters and an estimated thyroid size by palpation or measurement by 
ultrasonography or scintigraphy [26, 23, 25].
The majority of patients cure with a single RAI dose [11, 13]. Many physicians 
prefer a single high RAI dose, which leads to hypothyroidism. Cure rate high dose 
reach 85% - 94.4%, and 66–74% for low dose [4, 11, 14]. A single high dose or abla-
tive dose concept is preferred by a physician today. It can avoid patients’ frequent 
visits and laboratory testing for hypothyroid onset detection. It decreases the risk of 
persistent or recurrent hyperthyroidism [23]. A low dose is administered to achieve 
a euthyroid state to avoid hypothyroidism. 50%–90% of patients become hypothy-
roidism within 3–12 months [13]. Around 14% of hyperthyroid patients required 
second therapy. Persistence hyperthyroidism showed 7.3% after received 555 MBq 
(15 mCi) RAI [12, 13].
On the other hand, the low activity dose is generally not recommended because 
many patients need RAI retreatment. Furthermore, most patients will become 
hypothyroid after RAI [4, 23, 25]. Finally, therapy aims to control hyperthyroidism 
and render the patient to be hypothyroidism. The therapy outcome can be accom-
plished equally by administering a fixed RAI activity dose or calculating the activity 
based on the thyroid RAIU and size.
6. Patient preparation
Certain evaluations for adequate treatment include the treatment history such 
as ATDs, food or medication containing iodine that blocked radioiodine uptake 
that needs to discontinue before the treatment, and the duration of their period as 












Vitamins containing iodine 7–10 days
Amiodarone 3–6 months






Pharmaceuticals containing iodine block of RAI uptake [4, 6, 11, 23, 25].
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The patient should also be advised to avoid meals for at least 2 hours before and 
2 hours after the oral administration of RAI. Large meals can slow the absorption of 
RAI. Laboratory results, including free T4, free T3, Thyroid-stimulating hormone 
(TSH). Thyroid scintigraphy is used to assess the potential variability distribution 
of RAI in the thyroid gland. Graves’ disease scintigraphy pattern is a diffuse high 
uptake at the thyroid gland. It can differentiate between Graves’ disease with toxic 
adenoma and toxic multinodular goiter, as shown in Figure 3. Ultrasonography 
assessment may be useful if patients have a contraindication for the scintigraphy, 
such as during breastfeeding and pregnancy [6]. The choice of testing depends on 
cost, local availability, and expertise. RAIU measurements are not required when 
fixed activities are used. Thyroid ultrasonography can be used to determine thyroid 
volume. Pregnancy test for child-bearing females within 72 hours before the RAI 
administration, and when pregnancy is excluded, the test can be omitted.
For patients with ophthalmopathy, RAI can exacerbate existing Graves’ ophthal-
mopathy (GO) [11, 12, 23]. Smokers, high serum triiodothyronine pre-treatment, 
posttherapy hypothyroidism, and thyroid-stimulating receptor antibody are also 
associated with an increased risk of developing or worsening ophthalmopathy [23]. 
Steroids prevent the risk of RAI-induced ophthalmopathy without influence the 
outcome of therapy. Mild and active ophthalmopathy pre-exists patients with high-
risk factors associated with development or worsening of ophthalmopathy should 
receive steroid prophylaxis [25, 27, 28].
RAI therapy may need to be repeated. Patients also need a long-term follow- up 
because of the likelihood of eventual hypothyroidism and very uncommon side 
effects. Written information must be provided, and the patient should obtain writ-
ten informed consent before therapy.
7. Contraindication
Absolute contraindications of RAI are in pregnancy and during breastfeed-
ing and in patients who cannot comply with radiation safety regulations. Relative 
contraindications are uncontrolled hyperthyroidism and active thyroid orbitopathy 
Figure 3. 
Scintigraphy thyroid showed enlargement of both thyroid lobes, with high diffuse uptake of a Tc-99 m 
pertechnetate.
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(especially in smokers) [4, 6, 12, 25]. RAI is not contraindicated in large goiters, 
even if partially retrosternal or intrathoracic [25]. A higher cure rate reaches up to 
96%, even for thyroid size of more than 40 gram [12].
8. Adverse effects
Some patients, especially those who have large thyroid mass, may notice a 
transient swelling of goiter for approximately one week after therapy, salivary 
gland discomfort, or dyspnoea. Nausea that could develop into vomiting depends 
on the amount of administered activity for RAI. Antiemetic treatment can reduce 
the symptom. The effects are infrequent when the patients received <1.1 103 MBq 
(<30 mCi). Those effects are usually observed on a high dose >3.7 103 MBq  
(> 100 mCi) of RAI [29].
RAI treatment can cause a transient exacerbation of hyperthyroidism. The 
β- adrenergic blocker should be considered in symptomatic and asymptomatic 
patients who have hyperthyroidism risk (i.e., elderly patients and patients with 
comorbidities) [6]. Even though it is rare, the radiation can induce thyroiditis and 
thyroid hormone release into the circulation leading to thyroid storm precipitation 
[4, 6, 12]. The condition is more likely occurring in patients with a large thyroid 
mass and who received higher RAI activities. Elderly patients and patients with sig-
nificant pre-existing heart disease, severe systemic illness, or debility may benefit 
from pre-treatment with ATDs. However, ATDs should be withdrawn for one week 
before RAI therapy and resumed a week afterward [4, 6, 23, 25].
The aim of RAI therapy in GD is to control hyperthyroidism and render hypo-
thyroidism. It is easier to manage hypothyroidism with levothyroxine and fewer 
complications compared to treat hyperthyroidism with ATDs in the long term, 
leading to undesirable therapy effects [30]. The number of mortality reduced in 
hyperthyroid patients who become hypothyroidism after RAI therapy. The condi-
tion is implying the survival advantages of hyperthyroidism control. The risk of 
mortality of patients with hyperthyroidism, whether caused by cardiovascular or 
cancer, appears to be driven by thyroid hormone excess [4, 31].
9. Malignancy
The challenge of RAI’s late effect is concern developing the risk of malignancy 
after RAI treatment. Based on multi-center trials, there was no association of any 
clinical malignancy of RAI for the therapy. [7, 9, 11, 13, 23, 29, 31]. The malignancy 
is associate with a small risk of pre-existing or coexisting thyroid cancer in patients 
with toxic nodular goiter. Graves’ disease was not related to cancer development 
after RAI therapy [23].
10. Pregnancy
Conception should be delayed after six months of the therapy. The same period 
applies for males to allow irradiated spermatozoa and complete ovarian recovery 
for patients without undergone gonadal function and thyroid hormone under 
control [12]. Child-bearing women have no evidence of decreased fertility after 
received RAI treatment and no adverse outcome on subsequent pregnancies [32]. 
The incidence of intrauterine growth restriction, neonatal gender, and premature 
birth did not significantly differ between patients who received RAI therapy and 
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antithyroid drugs (ATDs). However, a higher abortion rate was found in Graves’ 
disease patients who received RAI and ATDs [33].
Furthermore, patients with intractable Graves’ disease and too high thyroid-
stimulating receptor antibody who want to pregnant soon should not receive 
radioiodine therapy to avoid developing fetal or neonatal hyperthyroidism [34]. 
RAI exposures in the first ten weeks of pregnancy do not affect fetal growth, but 
after ten weeks, the exposures can affect the growth [35]. Studies reported have 
no evidence of genetic damage and congenital anomaly, miscarriage, and preterm 
birth in patients who received RAI with the general population [7, 11, 13, 25, 36–38].
11. Follow-ups
Long-term follow-up after RAI therapy is needed. The likelihood of eventual 
hypothyroidism can occur within 2–3 months after therapy or even decades later, 
with a small, ongoing annual incidence. Lifelong thyroid hormone supplementa-
tion would then become necessary and should be started when thyroid-stimulating 
hormone elevation is detected and should have as its goal a euthyroid, symptom-
free state [23]. Transient hypothyroidism is reported in 3–20% of cases. It does not 
invariably lead to permanent hypothyroidism, but thyroid hormone supplementa-
tion is generally recommended.
12. Conclusions
RAI therapy is safe as definitive therapy and cost-effective for Graves’ disease 
definitive treatment. The treatment has to be individualized. Patients should fully 
understand the treatment procedures to reach the desired outcome and handle the 
risks and adverse effects. Three approaches for determining the administered RAI 
activity doses. 1. Based on the calculation of thyroid volume and the RAI uptake 
24 hours. 2. Based on thyroid volume, RAI uptake, effective half-life. 3. Fixed 
activity dose. However, the effectiveness is an equally successful outcome between 
them. RAI treatment aims in GD is to control hyperthyroid rather than avoidance of 
hypothyroidism. Hypothyroidism can occur within the first three months after RAI 
therapy or even decades later. Lifelong follow-up is needed to ensure recurrence of 
disease, and hypothyroidism is detected. Thyroid hormone supplementation would 
then become necessary and should be started when thyroid-stimulating hormone 
elevation is detected. Long-term studies show that radiation does not induce genetic 
damage or malignancy. However, conception should be delayed at least for six 
months after the therapy. So, the physician needs to provide written information for 
the patients to avoid miss interpretation.
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